Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masanori Fujii has a total of 147 co-authors. Here are the top co-authors by number of shared publications:

  • Takeshi Nabe

    Laboratory of Immunopharmacology, Faculty of Pharmaceutical Sciences, Setsunan University

    32 shared publications
  • Nobuaki Mizutani

    Kobe Pharmaceut Univ, Dept Pharmacol, Kobe, Hyogo 6588558, Japan

    16 shared publications
  • Shigekatsu Kohno

    Department of Pharmacology, Division of Pathological Sciences, Kyoto Pharmaceutical University, Kyoto, Japan

    16 shared publications
  • Susumu Ohya

    Department of Pharmacology, Division of Pathological Sciences, Kyoto Pharmaceutical University, Yamashina, Japan

    6 shared publications
  • Susumu Ohya

    Department of Pharmacology, Division of Pathological Sciences, Kyoto Pharmaceutical University, Kyoto 607-8414, Japan

    6 shared publications
  • Shin Yoshino

    Kobe Pharmaceut Univ, Dept Pharmacol, Kobe, Hyogo 6588558, Japan

    5 shared publications

Latest Publications

  • Open Access

    STIM/Orai-mediated calcium entry elicits spontaneous TSLP overproduction in epidermal cells of atopic dermatitis mice

    by Masanori Fujii, Shuhei Kobayashi, Ayane Ueda, Misaki Sakagami, Rieko Matsui, Yumeka Yamada, Takeshi Nabe, Susumu Ohya

    Aim: Atopic dermatitis (AD) is a pruritic, chronic inflammatory skin disease. Thymic stromal lymphopoietin (TSLP) is highly expressed in the epidermis of patients with AD and induces T helper 2 (

  • Open Access

    Tacrolimus suppresses itch-related response in diet-induced atopic dermatitis model mice by reducing chloroquine-sensitive sensory neurons

    by Masanori Fujii, Shota Bspharm Imahori, Misao Nakayama, Takeshi Nabe, Susumu Ohya

    Introduction: Itch (or pruritus) is a common symptom of atopic dermatitis (AD), which significantly decreases the patient’s quality of life. Tacrolimus ointment reduces pruritus in AD; however, the underlying mechanism is not fully understood. Methods: In the present study, we used a diet-induced AD mouse model to examine the antipruritic mechanism of tacrolimus. After induction of AD symptoms, the tacrolimus-containing ointment was applied once daily for 7 days. Responsiveness of isolated dorsal root ganglion (DRG) cells to various stimuli was examined by monitoring intracellular Ca2+ levels. Results: Repeated application of tacrolimus ointment attenuated spontaneous itch-related responses, even when skin barrier dysfunction, skin inflammation, and epidermal nerve sprouting were not ameliorated. Tacrolimus-treated mice also exhibited reduced scratching behavior induced by several pruritogens, such as histamine, SLIGRL-NH2, and chloroquine (CQ), although capsaicin-induced pain behavior was not affected. DRG cells from tacrolimus-treated mice showed significantly lower Ca2+ responses to CQ. Furthermore, a reduction in CQ-sensitive DRG neurons was observed after in vitro treatment with either tacrolimus or rapamycin. Discussion: CQ-sensitive (MrgprA3-expressing) DRG neurons are implicated as itch-specific sensory neurons. Therefore, topically applied tacrolimus may act directly on itch-signaling neurons, consequently suppressing various itch responses in AD mice.

  • Open Access

    The Pathogenic and Therapeutic Implications of Ceramide Abnormalities in Atopic Dermatitis

    by Masanori Fujii

    Ceramides play an essential role in forming a permeability barrier in the skin. Atopic dermatitis (AD) is a common chronic skin disease associated with skin barrier dysfunction and immunological abnormalities. In patients with AD, the amount and composition of ceramides in the stratum corneum are altered. This suggests that ceramide abnormalities are involved in the pathogenesis of AD. The mechanism underlying lipid abnormalities in AD has not yet been fully elucidated, but the involvement of Th2 and Th1 cytokines is implicated. Ceramide-dominant emollients have beneficial effects on skin barrier function; thus, they have been approved as an adjunctive barrier repair agent for AD. This review summarizes the current understanding of the mechanisms of ceramide abnormalities in AD. Furthermore, the potential therapeutic approaches for correcting ceramide abnormalities in AD are discussed.


  • Diet-Induced Mouse Model of Atopic Dermatitis

    by Masanori Fujii, Yuki Shimazaki, Takeshi Nabe

    Atopic dermatitis (AD) is a common skin disease characterized by chronic inflammation and itchiness. Although skin barrier dysfunction and immune abnormalities are thought to contribute to the development of AD, the precise pathogenic mechanism remains to be elucidated. We have developed a unique, diet-induced AD mouse model based on the findings that deficiencies of certain polyunsaturated fatty acids and starches cause AD-like symptoms in hairless mice. Here, we present a protocol and tips for establishing an AD mouse model using a custom diet modified from a widely used standard diet (AIN-76A Rodent Diet). We also describe methods for evaluating skin barrier dysfunction and analyzing itch-related scratching behavior. This model can be used not only to investigate the complex pathogenic mechanism of human AD but also to study the puzzling relationship between nutrition and AD development.


  • Open Access

    Search of itch-producing substance(s) released from skin cells of atopic dermatitis model mice

    by Masanori Fujii, Masayuki Nakashima, Chihiro Sakurai, Satoshi Tanaka

    Atopic dermatitis (AD) is a highly pruritic, chronic skin disease. Some mediators other than histamine are thought to play a major role in itch in AD. We have recently established an AD mouse model characterized by severe itch. In the present study, we searched itch-producing substance (pruritogen) released from skin cells of the model mice. Hairless mice were fed a special diet deficient in unsaturated fatty acids and starch to induce skin barrier dysfunction, and then ointments containing a crude extract of house-dust mite were repeatedly applied to the skin of the mice (AD mice). In AD mice, robust scratching behavior was observed especially after application of the mite extract, which was not suppressed by a histamine H1 receptor antagonist olopatadine. To identify the pruritogen(s), skin cells isolated from the AD mice were incubated in the medium containing the mite extract, and the conditioned medium was intradermally injected into normal mice. Scratching response was clearly induced by the samples derived from mite extract-treated AD skin cells, which was not inhibited by olopatadine. On the other hand, the mite extract itself did not induce scratching response. In conclusion, we successfully collected pruritogenic substance(s) released from skin cells of the AD model mice.

  • Open Access

    Current Understanding of Pathophysiological Mechanisms of Atopic Dermatitis: Interactions among Skin Barrier Dysfunction, Immune Abnormalities and Pruritus

    by Masanori Fujii

    Atopic dermatitis (AD) is a common chronic skin disease with multiple pathogenic factors including skin barrier dysfunction, immune abnormalities, and pruritus. This review summarizes components involved in these pathogenic factors. (1) Skin barrier dysfunction in AD could be due to the down-regulation of epidermal barrier components such as filaggrin, acylceramides, cornified envelope precursors, and claudin-1. (2) T helper type 2 (Th2) cell-derived cytokines, such as interleukin (IL)-4 and IL-13, and keratinocyte-derived cytokines, such as thymic stromal lymphopoietin (TSLP) and IL-33, contribute to Th2-mediated skin inflammation in AD. (3) IL-31, TSLP, IL-4, and IL-13 are able to directly activate primary sensory neurons to induce pruritus in AD, and increased susceptibility to itch (so-called alloknesis) is partly due to epidermal hyperinnervation. Importantly, the three key factors (skin barrier dysfunction, immune abnormalities, and pruritis) interact with each other, creating a positive feedback loop that leads to the induction and maintenance of AD. Therefore, a better understanding of not only each pathogenic factor but also their interactions is important to elucidate the complex pathophysiological mechanisms of AD, which will then lead to the development of new therapeutic strategies and drugs for the treatment of this common skin disease.


  • Open Access

    Brain allopregnanolone induces marked scratching behaviour in diet-induced atopic dermatitis mouse model

    by Masanori Fujii, Sayaka Ohgami, Erika Asano, Takanori Nakayama, Takahiro Toda, Takeshi Nabe, Susumu Ohya

    Allopregnanolone (ALLO) is a neurosteroid produced in the brain, but so far, no study has explored its link with itching. Herein, we used a diet-induced atopic dermatitis mouse model to examine whether exogenously administered and endogenously produced ALLO contribute to inducing scratching. Systemic administration of ALLO elicited robust scratching in the atopic dermatitis model, while it did not affect spontaneous and pruritogen-induced scratching in normal mice. ALLO caused scratching when administered intracisternally, but not when administered intrathecally or intradermally, suggesting the involvement of supraspinal mechanisms. Pharmacological analyses suggested that both γ-aminobutyric acid type A receptor activation and serotonin type 3 receptor inhibition were involved in ALLO-induced scratching. We next examined whether endogenously produced ALLO is involved in ethanol-induced scratching in atopic dermatitis mice, because ethanol administration increases ALLO in rodent brain. Acute ethanol administration increased brain ALLO levels, which coincided with increased scratching. Pre-treatment with finasteride, a synthetic ALLO inhibitor, suppressed ethanol-induced scratching and ALLO production in the brain. Collectively, our results demonstrated for the first time that ALLO administration caused marked scratching in atopic dermatitis mice, and ethanol-induced scratching may be mediated through endogenously produced brain ALLO.


  • Barbiturates enhance itch-associated scratching in atopic dermatitis mice: A possible clue to understanding nocturnal pruritus in atopic dermatitis

    by Masanori Fujii, Kaori Takeuchi, Yuna Umehara, Masafumi Takeuchi, Takanori Nakayama, Sayaka Ohgami, Erika Asano, Takeshi Nabe, Susumu Ohya


  • Eicosapentaenoic acid ethyl ester ameliorates atopic dermatitis–like symptoms in special diet–fed hairless mice, partly by restoring covalently bound ceramides in the stratum corneum

    by Masanori Fujii, Chie Ohyanagi, Naomi Kawaguchi, Hiroyuki Matsuda, Yoshitaka Miyamoto, Susumu Ohya, Takeshi Nabe

    Skin barrier dysfunction has a key role in the development of atopic dermatitis (AD). Covalently bound ceramides (Cer), which are essential lipids for permeability barrier homoeostasis, are reportedly decreased in the stratum corneum (SC) of AD patients. Hairless mice fed a special diet develop pruritic dermatitis resembling human AD. Our previous study found that oral administration of the n‐3 polyunsaturated fatty acid α‐linolenic acid ameliorated skin barrier dysfunction in AD mice with concomitant increase in serum eicosapentaenoic acid (EPA). In this study, we examined the effects of EPA ethyl ester (EPA‐E) on diet‐induced AD in hairless mice. Oral administration of EPA‐E ameliorated skin barrier dysfunction and pruritus in AD mice. In the SC of AD mice, covalently bound Cer were markedly diminished. EPA‐E administration restored the lack of bound Cer. Our findings imply the possible therapeutic clinical application of EPA‐E in the treatment of human AD.


  • Pathogenesis of Diet-induced Atopic Dermatitis in Hairless Mice

    by Masanori Fujii

    Atopic dermatitis (AD) is a common pruritic chronic skin disease. AD pathogenesis remains elusive, but may involve complex interplays among skin barrier dysfunction, Th2 inflammation, and pruritus. Current treatments for AD are still limited to symptomatic therapies. We previously showed that HR-1 hairless mice fed a special diet (HR-AD) develop AD-like symptoms; however, the ingredient(s) causing dermatitis remain unclear. In this study, we examined whether the deficiency of certain polyunsaturated fatty acids (PUFAs) was involved in the diet-induced AD pathogenesis. In the serum of HR-AD-fed mice, levels of linoleic acid (LA, 18:2n-6) and α-linolenic acid (ALA, 18:3n-3), as well as their metabolites, were markedly decreased. HR-AD-induced AD symptoms were significantly ameliorated by LA supplementation, and to a lesser extent by ALA supplementation. In addition, LA metabolites, such as γ-linolenic acid and arachidonic acid, had effects similar to those of LA. Further, using semi-purified custom diets, we attempted to reproduce HR-AD-induced AD symptoms. Unexpectedly, a deficiency in unsaturated fatty acids (UFAs) alone caused mild symptoms. However, several modifications of fat and carbohydrate components in the diet revealed that dietary deficiencies of UFA and cornstarch were required to fully induce severe AD symptoms. Furthermore, we examined the influence of genetic background on the development of diet-induced AD and found that a hypomorphic mutation in the hairless gene Hr, encoding a nuclear receptor (NR) corepressor, was essential for the complete development of diet-induced pruritic atopic skin. Thus, our findings suggest that certain PUFAs and NRs are new, potential therapeutic targets for treating AD.